We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Pleiotrophin Stimulates Expansion of Cord Blood Stem Cell Cultures

By LabMedica International staff writers
Posted on 29 Mar 2010
Researchers have identified a growth factor that stimulates the expansion of stem cell cultures from cord blood and that may make populations of such cells useful for treatment of patients lacking the cellular machinery --due to chemotherapy or radiation treatment, for example--for production of blood cells.

Investigators at Duke University (Durham, NC, USA) worked with a growth factor called pleiotrophin. More...
This growth factor is known by several other names including Neurite Growth-promoting Factor 1 (NEGF1), Heparin Affin Regulatory Peptide (HARP), or Heparin Binding Growth associated molecule (HB-GAM). It is an 18-kDa molecular weight growth factor that has a high affinity for heparin. During embryonic and early postnatal development, pleiotrophin is expressed in the central and peripheral nervous system and also in several nonneural tissues, notably lung, kidney, gut, and bone.

In the current study, the investigators treated mouse bone marrow hematopoietic stem cells (HSCs) with pleiotrophin. They also treated cultures of human cord blood cells with the growth factor as well as administrating it in a systemic fashion to irradiated mice.

Results published in the March 21, 2010, online edition of the journal Nature Medicine revealed that pleiotrophin stimulated a ten-fold expansion of mouse bone marrow stem cells. Treatment of human cord blood cultures resulted in substantially increased severe combined immunodeficient (SCID)-repopulating cell counts as compared to input and cytokine-treated cultures. Systemic administration of pleiotrophin to irradiated mice caused a pronounced expansion of bone marrow stem and progenitor cells, indicating that pleiotrophin was a regenerative growth factor for HSCs. So far, there has been no evidence that use of pleiotrophin could trigger formation of cancer cells, since the investigators have not seen any evidence of cancer in mice up to six months after treatment with pleiotrophin.

"These results confirmed that pleiotrophin induces stem cell regeneration following injury,” said senior author Dr. John Chute, professor of cell biology at Duke University. "Perhaps more importantly, systemic treatment with pleiotrophin may have the potential to accelerate recovery of the blood and immune system in patients undergoing chemotherapy or radiotherapy. At this point, any progress we can make that helps us better understand which biological pathways are activated in stem cells in response to pleiotrophin will help move the discovery forward.”

Related Links:

Duke University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Portable POCT Blood Gas Analyzer
BD100
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.